Product Name :
UKI-1
Description:
UKI-1 (UKI-1C) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells.
CAS:
220355-63-5
Molecular Weight:
613.81
Formula:
C32H47N5O5S
Chemical Name:
ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[2,4,6-tris(propan-2-yl)benzenesulfonamido]propanoyl]piperazine-1-carboxylate
Smiles :
CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC1C=C(C=CC=1)C(N)=N)NS(=O)(=O)C1C(=CC(=CC=1C(C)C)C(C)C)C(C)C
InChiKey:
ISJSHQTWOHGCMM-NDEPHWFRSA-N
InChi :
InChI=1S/C32H47N5O5S/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34)/t28-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Dabrafenib} medchemexpress|{Dabrafenib} MAPK/ERK Pathway|{Dabrafenib} Purity & Documentation|{Dabrafenib} In Vivo|{Dabrafenib} supplier|{Dabrafenib} Autophagy}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
UKI-1 (UKI-1C) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells.|Product information|CAS Number: 220355-63-5|Molecular Weight: 613.81|Formula: C32H47N5O5S|Chemical Name: ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[2,4,6-tris(propan-2-yl)benzenesulfonamido]propanoyl]piperazine-1-carboxylate|Smiles: CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC1C=C(C=CC=1)C(N)=N)NS(=O)(=O)C1C(=CC(=CC=1C(C)C)C(C)C)C(C)C|InChiKey: ISJSHQTWOHGCMM-NDEPHWFRSA-N|InChi: InChI=1S/C32H47N5O5S/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34)/t28-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 100 mg/mL (162.92 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Dehydroepiandrosterone} site|{Dehydroepiandrosterone} Metabolic Enzyme/Protease|{Dehydroepiandrosterone} Purity & Documentation|{Dehydroepiandrosterone} References|{Dehydroepiandrosterone} manufacturer|{Dehydroepiandrosterone} Epigenetics} |Shelf Life: ≥12 months if stored properly.PMID:29844565 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|UKI-1 (WX-UK1; 0.1-1.0 μg/mL) treatment shows a decrease of tumor cell invasion by up to 50% is achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa. UKI-1 (WX-UK1) interferes with the plasminogen activation system at 2 levels: it inhibits plasmin formation directly and via inhibition of uPA. In vitro invasion models with highly invasive fibrosarcoma and breast cancer cells showed that UKI-1 effectively inhibits migration of the cells through fibrin matrices.|In Vivo:|UKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models.|Products are for research use only. Not for human use.|
